← ANALYST RATINGS · TIPRANKS
Inhibikase Therapeutics (IKT): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy1 Hold0 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $5.58, the highest $8.00, the lowest $1.50. The average is +238.4% from the last price of $1.65.
Analyst ratings 8
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.00 → $1.50−25.0% | Hold | −9.1% | Reiterated | 17.10.26on TipRanks 06:07 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.00 → $1.50−25.0% | Hold | −9.1% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.00 → $1.50−25.0% | Hold | −9.1% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 → $1.50−25.0% | Hold | −9.1% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.00 → $1.50−25.0% | Hold | −9.1% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 → $1.50−25.0% | Hold | −9.1% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| Andreas Argyrides★★★★★★★★★★#1658 · hits 46% · avg +10.2% | Chardan Capital | $1.50 | Hold | −9.1% | Initiated | 13.10.26on TipRanks 04:40 | −4.6%next day +3.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.00 | Hold | +21.2% | Reiterated | 30.09.26on TipRanks 01:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.00 | Hold | +21.2% | Reiterated | 30.09.26on TipRanks 01:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.00 | Hold | +21.2% | Reiterated | 30.09.26on TipRanks 01:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 | Hold | +21.2% | Reiterated | 30.09.26on TipRanks 01:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.00 | Hold | +21.2% | Reiterated | 30.09.26on TipRanks 01:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 | Hold | +21.2% | Reiterated | 30.09.26on TipRanks 01:05 | — | |
| Gaurav Maini★★★★★★★★★★#2199 · hits 88% · avg +29.5% | LifeSci Capital | $5.00 | Buy | +203.0% | Reiterated | 15.09.26on TipRanks 16:25 | +0.4%next day −1.6% · 5 days −9.0% | ↗ |
| Jason McCarthy★★★★★★★★★★#12398 · hits 30% · avg −13.6% | Maxim Group | $8.00 | Buy | +384.8% | Reiterated | 13.08.26on TipRanks Aug 14 11:25 | −0.3%next day +0.2% · 5 days −0.5% | ↗ |
| Mazahir Alimohamed★★★★★★★★★★#9079 · hits 50% · avg −1.5% | Oppenheimer | $5.00 | Buy | +203.0% | Reiterated | 12.08.26on TipRanks 08:15 | −2.3%next day −0.3% · 5 days +2.5% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $8.00 | Buy | +384.8% | Reiterated | 31.07.26on TipRanks 06:51 | −5.1%next day 0.0% · 5 days +9.8% | ↗ |
| Jason Zemansky★★★★★★★★★★#467 · hits 60% · avg +21.6% | Bank of America Securities | $6.00 | Buy | +263.6% | Reiterated | 27.07.26on TipRanks Jul 28 06:50 | +0.8%next day −1.9% · 5 days −8.5% | ↗ |
| Olivia Brayer★★★★★★★★★★#9632 · hits 39% · avg −1.2% | Cantor Fitzgerald | $4.00 | Buy | +142.4% | Reiterated | 18.05.26on TipRanks May 19 08:16 | −6.9%next day −1.8% · 5 days +4.0% | ↗ |
| Aydin Huseynov★★★★★★★★★★#12223 · hits 33% · avg −18.6% | Ladenburg Thalmann & Co. | $4.00 | Buy | +142.4% | Initiated | 04.03.26on TipRanks 06:55 | +1.4%next day −2.5% · 5 days +4.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Inhibikase Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $6.40 at a price of $2.06 (+211.4%); now: $5.58 at $1.65 (+238.4%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 12 | 10 | 7 | 6 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.11 (from $-0.16 to $-0.06). Last quarter: $-0.11.
Best top-analyst consensus in the sector · General
About Inhibikase Therapeutics
- CEO: Mark T. Iwicki
- Employees: 35
- 1000 N. West Street, Wilmington, DE, 19801, US
- www.inhibikase.com
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Data from the stock’s TipRanks forecast page, read 48 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗